Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

C Flowers; H Tilly; F Morschhauser; LH Sehn; JW Friedberg; M Trneny; JP Sharman; C Herbaux; JM Burke; M Matasar; S Rai; K Izutsu; N Mehta-Shah; L Oberic; A Chauchet; W Jurczak; YQ Song; Richard Greil; L Mykhalska; JM Bergua-Burgues; MC Cheung; A Pinto; HJ Shin; G Hapgood; E Munhoz; P Abrisqueta; JP Gau; J Hirata; YW Jiang; M Yan; C Lee; G Salles

Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

C Flowers
, H Tilly
, F Morschhauser
, LH Sehn
, JW Friedberg
, M Trneny
, JP Sharman
, C Herbaux
, JM Burke
, M Matasar
, S Rai
, K Izutsu
, N Mehta-Shah
, L Oberic
, A Chauchet
, W Jurczak
, YQ Song
, Richard Greil
, L Mykhalska
, JM Bergua-Burgues

MC Cheung, A Pinto, HJ Shin, G Hapgood, E Munhoz, P Abrisqueta, JP Gau, J Hirata, YW Jiang, M Yan, C Lee, G Salles

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	S358-S359
Journal	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume	22
Publication status	Published - 2022

Access to Document

https://www.webofscience.com/wos/woscc/full-record/WOS:000897948100377?SID=EUW1ED0C1BnpoaeIcpiLJHXxIVSJS

Cite this

Flowers, C., Tilly, H., Morschhauser, F., Sehn, LH., Friedberg, JW., Trneny, M., Sharman, JP., Herbaux, C., Burke, JM., Matasar, M., Rai, S., Izutsu, K., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, YQ., Greil, R., Mykhalska, L., ... Salles, G. (2022). Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 22, S358-S359. https://www.webofscience.com/wos/woscc/full-record/WOS:000897948100377?SID=EUW1ED0C1BnpoaeIcpiLJHXxIVSJS

Flowers, C ; Tilly, H ; Morschhauser, F et al. / Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022 ; Vol. 22. pp. S358-S359.

@article{c466019d30814db2bee29b891f6850ab,

title = "Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study",

author = "C Flowers and H Tilly and F Morschhauser and LH Sehn and JW Friedberg and M Trneny and JP Sharman and C Herbaux and JM Burke and M Matasar and S Rai and K Izutsu and N Mehta-Shah and L Oberic and A Chauchet and W Jurczak and YQ Song and Richard Greil and L Mykhalska and JM Bergua-Burgues and MC Cheung and A Pinto and HJ Shin and G Hapgood and E Munhoz and P Abrisqueta and JP Gau and J Hirata and YW Jiang and M Yan and C Lee and G Salles",

year = "2022",

language = "English",

volume = "22",

pages = "S358--S359",

journal = "CLINICAL LYMPHOMA MYELOMA \& LEUKEMIA",

issn = "2152-2650",

publisher = "Cig Media Group, Lp",

}

Flowers, C, Tilly, H, Morschhauser, F, Sehn, LH, Friedberg, JW, Trneny, M, Sharman, JP, Herbaux, C, Burke, JM, Matasar, M, Rai, S, Izutsu, K, Mehta-Shah, N, Oberic, L, Chauchet, A, Jurczak, W, Song, YQ, Greil, R, Mykhalska, L, Bergua-Burgues, JM, Cheung, MC, Pinto, A, Shin, HJ, Hapgood, G, Munhoz, E, Abrisqueta, P, Gau, JP, Hirata, J, Jiang, YW, Yan, M, Lee, C & Salles, G 2022, 'Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 22, pp. S358-S359. <https://www.webofscience.com/wos/woscc/full-record/WOS:000897948100377?SID=EUW1ED0C1BnpoaeIcpiLJHXxIVSJS>

Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study. / Flowers, C; Tilly, H; Morschhauser, F et al.
In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 22, 2022, p. S358-S359.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

AU - Flowers, C

AU - Tilly, H

AU - Morschhauser, F

AU - Sehn, LH

AU - Friedberg, JW

AU - Trneny, M

AU - Sharman, JP

AU - Herbaux, C

AU - Burke, JM

AU - Matasar, M

AU - Rai, S

AU - Izutsu, K

AU - Mehta-Shah, N

AU - Oberic, L

AU - Chauchet, A

AU - Jurczak, W

AU - Song, YQ

AU - Greil, Richard

AU - Mykhalska, L

AU - Bergua-Burgues, JM

AU - Cheung, MC

AU - Pinto, A

AU - Shin, HJ

AU - Hapgood, G

AU - Munhoz, E

AU - Abrisqueta, P

AU - Gau, JP

AU - Hirata, J

AU - Jiang, YW

AU - Yan, M

AU - Lee, C

AU - Salles, G

PY - 2022

Y1 - 2022

M3 - Abstract (Journal)

C2 - 36164048

SN - 2152-2650

VL - 22

SP - S358-S359

JO - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

JF - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

ER -

Flowers C, Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M et al. Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022;22:S358-S359.